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Optimizing Cost and Data Entry for Assignment of Patients to Clinical Trials Using 
Analytical and Probabilistic Web-Based Agents 
 
Bhavesh Dineshbhai Goswami 
 
ABSTRACT
 
A clinical trial is defined as a study conducted on a group of patients to determine the 
effect of a treatment. Assignment of patients to clinical trials is a data and labor intensive 
task. Usually, medical personnel manually check the eligibility of a patient for a clinical 
trial based on the patient’s medical history and current medical condition. According to 
studies, most clinical trials are under-enrolled which negatively affects their 
effectiveness. We have developed web-based agents that can test the eligibility of 
patients for many clinical trials at once. We have tested various heuristics for optimizing 
cost and data entry needed in assigning patients to clinical trials. Testing eligibility of a 
patient for many clinical trials is only feasible if it is cost and data entry efficient. Agents 
with different heuristics were then tested on data from current breast cancer patients at 
the Moffitt Cancer Center. Results with different heuristics are compared with each other 
and with that of the clinicians. It is shown that cost savings are possible in clinical trial 
 vi 
assignment. Also, less data entry is needed when probabilistic agents are used to reorder 
questions.  
  
 1 
Chapter 1 
Introduction
1.1 Introduction 
A clinical trial is an experimental research study that evaluates a specific new treatment 
for a specific population of patients. The trial protocol is a rulebook which clearly 
identifies the criteria for a patient to be eligible for the trial. The criteria is based on the 
medical history and the present medical condition of the patient. Some criteria are general 
information such as the age and sex of the patient while others requires specific tests be 
done to determine if the patient matches them. Eligibility is usually checked manually by 
a clinician, nurse or trial coordinator. In the absence of enough information to determine 
the eligibility of a patient, clinicians order tests needed to obtain the required information. 
Each test has some cost associated with it and studies show that if tests are reordered 
correctly, cost savings are possible [1, 11, 14]. Although clinicians can potentially reduce 
costs by ordering inexpensive tests first, test reordering is a complex optimization 
problem which has many parameters like the actual cost of the test, number of eligibility 
criterion decided by it, number of protocols in which the test is needed and the 
probability of the test resulting in an eligibility decision for the patient.   
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1.2 Significance 
Cancer is one of the major causes of death in United States resulting in 550,000 deaths 
annually. Cancer treatment is an active research area. Clinical trials are used to research 
new treatments. Accrual of patients to these clinical trials is of the utmost importance for 
the success of a trial. At any one time there are many active trials, and keeping track of 
them becomes a difficult task. Studies show that clinicians sometimes miss up to 50% to 
60% of the eligible patients [11, 22, 33]. In such a scenario, having a web-based agent 
with a central database of clinical trials that can be accessed through the internet by any 
willing institute can drastically improve accrual of patients. It may also ease the process 
of trial sharing among various institutes, which is difficult otherwise.  
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Chapter 2 
Previous Work
2.1 Software Agents 
A software agent is defined as an autonomous software entity that can interact with its 
environment to accomplish certain objectives without any direct input or supervision 
from its user. Software agents are used in a variety of fields like VLSI design, search 
engines, e-commerce applications, business processes, medical research, etc. Earlier use 
of AI in medical domains was primarily through expert systems for diagnosis and 
treatment suggestions. The primary difference between expert system and agent is that 
the agent changes dynamically according to the changes in its environment and that many 
agents can work together to accomplish certain task(s). The analytical and probabilistic 
agents, which we developed, dynamically change their heuristic parameter values as new 
information is received. The analytical agent modifies the rule graphs and cost 
information when it acquires new information, while the probabilistic knowledge base is 
updated on acquisition of new information, which dynamically changes the heuristic 
parameter values of the probabilistic agent. Also the analytical and probabilistic agents 
can work together to reorder the questions and assign patients to clinical trials. Due to the 
above facts, we term them as agents. 
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2.2 History 
Research in the use of Artificial Intelligence for medical diagnosis has been conducted 
since the early seventies. A variety of expert systems were developed for diagnosis and 
treatment of various diseases. The MYCIN system for diagnosis of bacterial diseases was 
developed by Shortliffee and colleagues [13]. It evolved from a chemical expert system 
called DENDRAL [8, 24, 25]. It was a rule-based system with if-then rules using the 
backward chaining process. The system gathered information about the patient and 
provided treatment recommendations with explanations of how the conclusion was 
reached.  MYCIN was found to be fairly accurate in the experiments conducted, which 
led to the development of various other medical expert systems. EMYCIN [7] was 
developed from MYCIN. It was a generic expert system shell where rules from any 
domain could be added to the knowledge base. A lung disease knowledge base was 
developed using EMYCIN and the resultant system was called PUFF [26]. An expert 
system called NEOMYCIN [9] was developed to train doctors by presenting them with 
practice cases, getting their diagnosis and correcting them when they made mistakes.  
2.3 Similar Systems 
Researchers have adopted many different approaches for systems to assign patients to 
clinical trials. A system called AIDS [28] was developed to assign patients to HIV 
clinical trial treatment protocols. It used Bayesian belief networks to manage uncertainty. 
It has a protocol driven mode, where each patient’s probability of eligibility is checked 
automatically for a new clinical trial protocol using the data patient has. EON [30] was 
made with reusability as a high priority. Thus they made four reusable basic components 
of the system. The knowledge base could be generated for any protocol based therapy. 
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ONCODOC [4, 5, 6, 19, 20] was developed to “enhance the accrual of patients in the 
best care plan.” It had non-metastatic breast cancer protocols encoded as decision trees. 
The goal was to enhance the usability of the system by providing flexibility in the 
interpretation of the results by clinicians. Clinicians incrementally assign values to the 
decision parameters while navigating through the decision tree. Thus it is halfway 
between knowledge representation and a static written description and allows both formal 
and informal aspects of the protocols to be implemented. It means that a clinician can 
make an explicit decision if a test result is borderline or can navigate through the 
remaining decision tree to see the underlying logic and make his decision. An important 
drawback of using decision trees is that you cannot test a patient for multiple trials at 
once. One will have to test a patient separately for each trial, and thus the time consumed 
will increase drastically when the patient’s eligibility is checked for many clinical trials. 
A system to assign patients to clinical trials was designed by Papaconstantinou 
and colleagues [10] using Bayesian networks. They were successful in implementing 
three clinical trials but concluded that the complexity of the Bayesian network immensely 
increased when new trials were being added. Another drawback was the difficulty in 
getting the prior probability relationships between different nodes of the network. Also, 
propagation of probabilities with data evidence was very slow. Another system DIAVAL 
[8] was also a Bayesian expert system for echocardiaography. It had the same problems 
discussed above. Smith and McNeely [2, 31] built an expert system to reorder tests for 
laboratory investigations of patients for general clinical problems. They used the 
ACQUIRE suite of expert system tools to design this system. Their results shows that the 
laboratory costs were reduced from mean $232 to $194 on tested patients.  
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Chapter 3 
System Design
3.1 System Overview 
The system is divided into three main parts (a) Knowledge entry system, (b) Agent and, 
(c) Testing system. Nikiforou [36] implemented the knowledge entry system. It is a web-
based system that has user-friendly interface for encoding the clinical trials into a form 
that is understood by the agents. Fletcher, Kokku [33] and colleagues have built the initial 
agent for matching of patients to clinical trials. We modified the way cost was dealt with 
in the system and conducted systematic experiments to evaluate the cost-savings by the 
system. We also added the probabilistic agents to the system and conducted experiments 
to compare the results. Figure 1 represents the basic structure of the system.  
As shown in Figure 1, the user interacts with the system through the web-based 
interface. A user can access old patient data, add new patients and enter data for existing 
patients. Each time new information is obtained about the patient, her eligibility is 
checked for the protocols selected. The patient is eligible, ineligible or more information 
is required to decide on eligibility for a particular protocol. If more information is needed 
to determine patient’s eligibility, the probabilistic agent calculates the eligibility 
probability based on the current data of the patient and probabilistic knowledge base of 
the system. 
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Figure 1: System Architecture 
 
The system augments its probabilistic knowledge base by gathering information 
entered for the current patients and its effect on the eligibility of the patient. After 
checking eligibility, if the patient has protocols for which eligibility is not yet decided 
upon, the reordering subsystem reorders the relevant questions using analytical and 
probabilistic agents. At all times, the system has an explanation subsystem which can 
provide an explanation for system’s decisions. More protocols can be added to the system 
using the knowledge entry system. The testing system is used to test new heuristics by 
Agent 
User Interface 
Knowledge Base 
Reordering Agents 
Agent for assigning patients 
to clinical trials 
Probabilistic Analytical Probabilistic Knowledge 
Patient database 
General knowledge and 
implication 
Domain specific 
knowledge 
Knowledge entry system 
Testing system 
User Explanation sub-system 
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creating many new patients and testing the effectiveness of the system without human 
intervention.    
3.2 Knowledge Representation 
The system incorporates domain knowledge in the form of medical tests, questions and 
eligibility criteria. A test can be entered into the system with its name and cost. A list of 
questions that are answered by that test are then entered. For example, as shown in Figure 
2, Mammogram test answers questions i) What is the cancer stage? ii) Does the patient 
have invasive cancer? Clinical trial protocols can then be entered into the system, which 
are essentially a set of rules composed of the entered questions. The eligibility of the 
patient for a particular protocol can then be tested using the agent. There is a web-based 
interface to accomplish all these tasks.  
 
 
Figure 2: Example of Tests and Questions 
General Questions    Cost: $0 
 
What is patient’s sex?    
 
What is patient’s age?    
 
Mammogram     Cost: $150 
 
What is the cancer stage?      
 
Does the patient have invasive cancer?     Yes        No       Unknown    
  
I  II  III  IV 
Female    Male 
CT scan (Head)    Cost: $850 
 
Are there any symptoms of metastatic       Yes        No       Unknown 
disease in brain?   
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3.2.1 Medical Tests 
Medical tests that are performed on patients to obtain information needed to determine 
their eligibility are entered into the system along with the cost incurred to perform that 
test. Each test, when performed, gives us information about the patient which is used to 
determine her eligibility. This information is stored in the form of questions.  
3.2.2 Questions 
A question can be any of the three forms: (a) Yes/No, (b) Multiple choice and (c) 
Numeric. A Yes/No question is the one where the answer to the question is yes, no or 
unknown. Similarly, multiple choice questions have a list of two or more answers to 
select the answer from. A numeric question has some numeric value as its answer. Figure 
2 shows some tests and the questions associated with them. 
3.2.3 Eligibility Criteria 
The clinical trial eligibility criteria is essentially a logical expression of questions. Figure 
3 shows an eligibility criteria and the corresponding logical expression. The system keeps 
asking for data until either the expression in Figure 3(a) is TRUE or the expression in 
Figure 3(b) is FALSE, which means that the patient is eligible or ineligible respectively. 
For example, let’s assume that a patient’s eligibility is checked for the given trial which 
has the eligibility criteria shown in Figure 3.  
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Figure 3: Eligibility Criteria and its Acceptance and Rejection Expressions 
 
Assume the system already has the data that the patient is female and that she is 
postmenopausal. The remaining pertinent information to be obtained is (a) Age, (b) If 
there is metastatic disease in the head and (c) If cancer is invasive. We do not need to 
perform any tests to know a patient’s age so that information is free to us. On the other 
hand, we need to perform a mammogram to check if the cancer is invasive and it costs 
$150. Similarly, to check if there is metastatic disease in brain, we need to perform a CT 
scan of the head, which costs $850. The cost optimization problem here is to see if it is 
(a) Acceptance Expression 
 
sex = FEMALE AND 
age    18 AND 
age   50 AND 
{ postmenopausal = YES OR use_contraceptive = YES} AND 
invasive_cancer = NO AND 
brain_metastatic = NO 
 
 
(b) Rejection Expression 
 
sex = MALE OR 
age   18 OR 
age    50 OR 
{ postmenopausal = NO AND use_contraceptive = NO} OR 
invasive_cancer = YES OR 
brain_metastatic = YES 
 
 
 
1. Female of age 18 to 50 years. 
2. Must be postmenopausal or using contraceptive. 
3. Should not have metastatic disease in brain. 
4. Cancer should not be invasive. 
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more beneficial to order a CT scan of the head or a mammogram. A mammogram looks 
like a better alternative at the first glance as it costs much less then CT scan. However 
there are other issues which are important too.  
For example if most patients have invasive cancer, then it will be more efficient to 
go for a CT scan, even though it is costs more, as the probability of a patient having 
invasive cancer is high and it requires us to do a CT scan anyways after a mammogram is 
performed. Also, when one tests for multiple protocols at once, many protocols might 
need information which can be obtained from a single test, so that test gets priority. Thus 
test ordering is a complex optimization task. The system keeps asking questions with 
continued reordering until it can either determine that the acceptance expression is TRUE 
or rejection expression is TRUE.  
3.3 Algorithm 
As described above, the system stores eligibility criteria of different trials in the form of 
rules which are described as logical expressions of different questions. While computing 
eligibility we store the rules in the form of nodes.  
 
Figure 4: Acceptance Expression Graph 
sex = Female 
age    18 
age   50 
use_contraceptive 
= YES 
postmenopausal 
= YES 
AND 
brain_metastatic 
= YES 
invasive_cancer 
= YES 
OR 
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Figure 5: Rejection Expression Graph 
 
Two graphs are created, one for the acceptance expression and the other for the 
rejection expression. The base node of the acceptance expression graph is the AND node 
which represents the eligibility of a patient. It represents the conjunction of conditions 
that are needed to be satisfied in order for a patient to be eligible for a protocol. Figure 4 
shows the acceptance expression graph for eligibility criteria defined in Figure 3. Figure 
5 is the rejection expression which represents the ineligibility criteria. The base node of 
this graph is an OR node. The OR node represents a disjunction of conditions that rule 
out a patient for a trial. The patient is eligible if the AND node of the acceptance 
expression is TRUE, ineligible if the OR node of the rejection expression is TRUE and 
the eligibility is not decided if neither of them is true. Only one of them can be TRUE at a 
time for a given patient. The system will keep asking questions until one of the base 
nodes is determined to be TRUE.  
sex = Male 
age   18 
age    50 
use_contraceptive 
= NO 
postmenopausal 
= NO 
OR 
brain_metastatic 
= NO 
invasive_cancer 
= NO 
AND 
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3.3.1 Test Reordering 
Analytical and probabilistic agents are used to reorder tests for the optimization of cost 
and data entry. Analytical heuristics are based on test cost and the structure of the 
rejection and acceptance expressions. Probabilistic agents use probabilistic data 
accumulated over time by the system. 
3.3.1.1 Analytical Reordering Agent 
The analytical reordering agent uses three heuristic parameters to reorder tests. The first 
parameter  is the most fundamental one, which is the cost of a test. The more expensive 
the test, the less likely it is for the system to obtain information associated with that test. 
Less expensive tests get priority over the more expensive ones. Although this heuristic 
looks straightforward, it has inherent drawbacks. For example imagine a scenario where 
the agent has to decide between ordering two tests, test A and test B, where test B costs 
twice as much as test A. Although the first thought would be to order test A ahead of test 
B, that may not always be the case. Imagine a scenario where test A’s results are almost 
always favorable for the patients, and almost no patient gets ruled out of a protocol due to 
test A’s results. In such a scenario it will be more efficient to order test B ahead of test A. 
When a patient is tested for multiple trials at once, a certain test might be needed to 
determine eligibility for more than one trial. That is the second heuristic parameter. The 
number of clinical trials that need a particular test be done, to determine the eligibility, is 
taken as a heuristic parameter. The probability of a test being ranked highest is linearly 
proportional to the number of trials that need it.  
The third heuristic parameter is the number of clauses that include questions 
answered by that test in the acceptance expression. To calculate this, the acceptance 
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expression needs to be converted into Disjunctive Normal Form (DNF). Converting a 
graph into DNF can take a considerable amount of processing time if the graph has many 
OR nodes.  
For example consider a simple expression (a ∨ b ∨ c) ∧ (e ∨ f ∨ g) ∧ (h ∨ i ∨ j) 
with nine AND nodes and 1 OR node. After converting it into DNF the expression looks 
like that in Figure 6 
 
 (a ∧ e ∧ h) ∨ (a ∧ e ∧ i) ∨ (a ∧ e ∧ j) ∨ (a ∧ f  ∧ h) ∨ (a ∧ f ∧ i) ∨ (a ∧ f  ∧ j) ∨ 
(a ∧ g ∧ h) ∨ (a ∧ g ∧ i)  ∨ (a ∧ g ∧ j) ∨ (b ∧ e ∧ h) ∨ (b ∧ e ∧ i) ∨ (b ∧  e ∧ j) ∨  
(b ∧ f  ∧ h) ∨ (b ∧ f  ∧ i) ∨ (b ∧ f ∧ j) ∨ (b ∧ g ∧ h) ∨ (b ∧ g ∧ i) ∨ (b ∧ g ∧ j) ∨ 
(c ∧ e ∧ h) ∨ (c ∧ e ∧  i) ∨ (c ∧ e  ∧ j) ∨ (c ∧ f  ∧ h) ∨ (c  ∧  f ∧  i) ∨ (c  ∧ f  ∧ j) ∨ 
(c ∧ g ∧ h) ∨ (c ∧ g  ∧ i) ∨ (c ∧ g  ∧ j) 
Figure 6: Expansion of CNF to DNF 
 
As shown in Figure 6, the expression now has 27 AND nodes and one OR node. For 
large expressions, this conversation takes considerable computing time and thus can be a 
drawback. After the conversion, for each test, the number of clauses that depend on a 
question belonging to that test is calculated. The tests that are needed in more clauses get 
priority.  
After the system gets any new information, it regenerates the graphs and 
recalculates heuristics values. After calculating all three parameters of all tests, the agent 
does a linear combination of the parameter values and orders the tests using it.  
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3.3.1.2 Probabilistic Reordering Agent 
Most people who have used a probabilistic approach towards expert systems or agents 
have used Bayesian Networks. There are many inherent problems with this approach and 
the prime ones are: (a) Bayesian Networks are very complex and it takes a lot of time to 
build new networks when new trials are added (b) It is difficult to get initial relational 
probabilities between nodes of the network (c) It takes a lot of computational time to 
modify the conditional probability between nodes of the network in the wake of new 
evidence [10, 15]. In spite of the above drawbacks, they also have some critical 
advantages over analytical rule-based systems. The most important advantage 
probabilistic systems have is their ability to estimate eligibility probability in the absence 
of some information. Rule based systems cannot estimate the probability even in the 
absence of a single piece of information. Consider a protocol which has 20 eligibility 
rules, and 19 of them are met, which seemingly makes it likely for a patient to be eligible. 
A rule based system will still not be able to predict anything about the probability of the 
patient’s eligibility while a probabilistic system can estimate the eligibility of the patient 
using the prior probabilities that the system has. Probability estimation becomes 
important in certain cases, especially when you have many trials. The Moffitt Cancer 
Center at USF has about 15 active breast cancer trials at once. It is time-consuming and 
expensive to test patients for all trials. Thus rather than testing the patients for all trials, 
we can just test her eligibility for trials which show high initial eligibility probability. We 
can also use probabilistic knowledge accumulated over time by the system to reorder the 
tests.  
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To attempt to exploit the advantages of the probabilistic systems and to avoid its 
drawbacks, we used the probabilistic methods discussed below. The basic idea is to try to 
classify a patient as ineligible as soon as possible. The idea is that if a patient is 
ineligible, the information that is most likely to determine her ineligible should be 
obtained first. This would optimize the data-entry needed to decide upon a patient’s 
eligibility. The system gathers this probabilistic knowledge over time. For each question 
in the system, it keeps a log of how many times a question is asked and how many times 
a patient is ruled out for a particular trial after that question is answered. This gives us the 
probability of that question, when asked, ruling out a patient for a particular trial. So the 
approach would be to ask the question which has the highest probability of ruling out a 
patient first. When multiple trials are tested at once and same question is in the 
acceptance expression of more that one trial, we add the separate probabilities of the 
question for each trial. Note that the result of the summation can be greater then one, thus 
it is not a probability anymore. Rather it is summation value which, when higher, 
suggests a higher likelihood of determining a patient ineligible. 
These probabilities are also used to estimate the eligibility probability. Here we 
make an important assumption that all questions have independent probabilities. 
Although this assumption is not entirely true, it seems close enough. Most questions are 
either completely dependent on each other or are not at all dependent. For example if a 
patient has no positive lymph nodes, that means that the cancer stage is either 0 or I. Thus 
the two questions “Does the patient have positive lymph nodes?” and “What is the cancer 
stage?” are dependent on each other. We can take care of such situations by an 
implication sub-system. We can add implication rules in the system such as “If cancer 
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stage 0 or I then it implies that patient has no positive lymph nodes”. When system has 
information that the cancer stage is either 0 or I, the implication subsystem automatically 
generates information that no lymph nodes are positive and the system does not ask for 
that information. Thus, all such completely dependent questions are taken care of by the 
implication subsystem. There are very few questions which have a partial implication, 
like “If a patient is ER positive then there is an 80% chance of positive lymph nodes”. 
We ignore such conditional probabilities among questions and treat all questions as either 
completely dependent or independent.  
When we assume all questions to be independent, the eligibility criteria for a 
protocol becomes a set of independent questions which must have favorable answers for 
a patient to be eligible. Also we have the probability of how many times a question, when 
answered, was responsible for a patient being ineligible for a protocol. Thus we have 
probability of each question being answered favorably for eligibility. A patient will be 
eligible for a protocol when each answer is favorable. Thus the eligibility probability of a 
protocol will be the product of the favorable probabilities of all questions. When a 
question is answered and the answer meets the eligibility rules of the clinical trial, we can 
exclude it from our product and thus we get the new eligibility probability. As more 
questions answered fit the eligibility criteria, the eligibility probability increases. When a 
question’s answer does not fit the eligibility profile, the patient becomes ineligible and 
the eligibility probability becomes zero. When the patient becomes eligible the eligibility 
probability is 1. The eligibility probability varies between 0 and 1 when the eligibility of 
a patient is undecided.  
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Although the above mentioned approach gave good results when the computed 
probabilities were used to reorder questions (as discussed in the “Experiments and 
Results” section), the probabilities computed were not normalized and thus were very 
small numbers that did not give any meaningful feedback to the user. To compute 
probabilities that provide meaningful feedback, the Naïve Bayes approach appeared to fit 
well. We can think of the patient enrolment procedure as a classification problem. The 
classification classes will be “Eligible” or “Ineligible”. The attributes will be the 
questions and the values for the question are “Favorable for eligibility” or “Unfavorable 
for eligibility” for each clinical trial. We have a probability for each question to be 
favorable and unfavorable for each clinical trial. Thus we have a classification problem 
where we have probabilities for the occurrence of each attribute value. To use Naïve 
Bayes we also needed probabilities of occurrence of each classification type, which is 
“Eligible” or “Ineligible” in our case. We modified the system so that for each clinical 
trial, the system recorded how many patients were tested for that clinical trial and how 
many patients were decided to be eligible and ineligible. Thus, we could now use Naïve 
Bayes to calculate the eligibility probability of a patient with partial information.  
Let us assume that we have a clinical trial T with three questions Q1, Q2 and Q3. 
Out of 100 patients that were tested on the clinical trial, we found 40 to be eligible and 60 
to be ineligible. Question Q1 as asked 90 times and it disqualified patients 10 times, Q2 
was asked 80 times and disqualified patients 5 times, and Q1 was asked 70 times and 
disqualified patients 15 times.  Thus P(TE), the probability of patient being eligible for 
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protocol T is 100
40
. P(Q1), the probability that questions Q1 is answered favorably for 
clinical trial T is 90
80
. Similarly P(Q2) = 80
75
 and P(Q3) = 70
55
.  
So when we don’t have any information, i.e. we don’t have answers for any 
questions, then the probability of a given patient being eligible for clinical trial T is 100
40
. 
Now assume that we have answers to questions Q1 and Q2 and the answers are favorable 
for eligibility. Thus the new eligibility probability will be P(TE | Q1, Q2). According to 
Naïve Bayes: 
)T|P(Q )T| P(Q )P(T   )Q ,Q|P(T E2E1E21E =
 
P(Q1 |  TE)  is the probability that question Q1 was answered favorably for 
eligibility given the fact TE, which means that patient is eligible for clinical trial T. Now, 
if a patient is eligible for a clinical trial, all the questions must be answered favorably for 
eligibility. Thus P(Q1 |  TE) = 1. Similarly P(Q2 | TE) =1. Thus  ).P(T   )Q ,Q|P(T E21E =  
As shown, P(TE | Q1, Q2 …. Qn) will always be P(TE) regardless of the number of 
questions answered. Thus Naïve Bayes cannot be used in this case as the probabilities do 
not change dynamically when the acquisition of new information. For enhancing the 
estimation technique for the clinical trial probability, we then used Bayes rule. Using 
Bayes rule  
)Q ,P(Q 
)T|Q ,P(Q )P(T
  )Q ,Q | P(T
21
E21E
21E =
 
As explained before P(Q1, Q2 | TE) will be the probability that questions Q1, Q2 are 
favorable for eligibility given that the patient is eligible for protocol T. If the patient is 
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eligible then the questions answered will always be favorable and thus P(Q1, Q2 | TE) = 1. 
Also we have assumed that all questions are independent and thus 
P(TE | Q1, Q2) = P(TE | Q1) P(TE | Q2)  
Substituting all this values, we get the new equation as  
)P(Q )P(Q 
)P(T
  )Q ,Q | P(T
21
E
21E =
 
Substituting the values of P(TE), P(Q1) and P(Q2) we get the value 0.48 for the 
equation. Thus after answering two questions Q1 and Q2, the eligibility probability of a 
patient for clinical trial T is 48%. 
The generic equations for eligibility probability for a clinical trial when we have 
favorable answers for eligibility for n questions will be 
)P(Q ..... )P(Q )P(Q 
)P(T
  )Q ......... Q ,Q | P(T
n21
E
n21E =
 
3.4 Testing System 
Every time a new reordering agent is implemented or the current agent is modified, its 
effectiveness needs to be determined. To obtain data that can be used to compare 
different agents’ effectiveness, a certain number of patients need to be assigned to clinical 
trials using the clinical trial assignment system that incorporates the reordering agents in 
question. Performing the operation of repeatedly assigning numerous patients to clinical 
trials using the system is a time consuming and labor intensive task. The manual data 
entry required severely increases the time needed to perform such experiments and limits 
the number of patients that can be tested. To overcome such shortfalls, a testing system 
was developed.  
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The testing system takes a list of patient names, a list of clinical trials and path to 
the patient assignment system as its arguments. It then autonomously checks the 
eligibility of the list of patients for the list of clinical trials using the assignment system 
which is accessible at the path specified in the argument. The patients in the patient list 
already have had their eligibility manually determined for a set of clinical trials. For each 
such patient in the patient list, the testing system creates a new test-patient and attempts 
to determine the eligibility of the patient for the list of clinical trials provided using the 
clinical trial assignment system whose link is passed as a parameter. The clinical trial 
assignment system reorders questions and presents the question list with the topmost 
question being the most important, according to the reordering parameters. The testing 
system answers the topmost question of that list, by obtaining the answer from the 
patient’s data that was manually added into the system. After the answer is obtained, the 
clinical trial assignment system regenerates the reordering parameter values and reorders 
the questions.  
At the end of the execution, the testing system generates a summary file which 
contains information for each patient such as the number of questions asked, cost, 
eligibility status of the clinical trials, etc. Thus the testing system makes it fast, effective 
and easy to test different heuristics without human intervention. The testing system works 
autonomously, but it requires human intervention in certain cases. When the clinical trial 
assignment system presents the reordered questions list and the testing system does not 
have the answer to the topmost question on the list, it requires human intervention to find 
out the answer to the question. This generally happens because the original patient data 
do not contain answers for all questions. The clinical trial assignment system stops 
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presenting further questions for a trial when the patient is either eligible or ineligible for 
that trial. So a patient’s data generally do not contain answers to all the questions. When a 
new heuristic is implemented, questions are reordered differently and often a question 
which is unanswered in the original patient data is presented. The testing system would 
not be able to find data for it and thus it seeks human intervention. In the summary file, 
all such patients are listed. A user can then look at medical database of the hospital or 
patient’s chart to obtain the information and enter it into the system.  
The code for the testing system is written in PERL, while the rest of the system is 
coded in C. The code can be found in the CD ROM presented with the thesis.  
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Chapter 4 
User Interface
4.1 Interface Design 
The system provides a user-friendly web-based interface for the user. The whole system 
is designed in such a way that there is a central system and clinical personnel can access 
it from anywhere via the internet. A user can enter new patients and check their eligibility 
for all the available trials. Figure 7 shows the control flow diagram of the user interface. 
 
 
 
Figure 7: User Interface Design 
The user starts by entering the name and identification number for the patient as 
shown in Figure 8. The combination of name and identification number should be unique 
for all the patients. The user also has search options to find patients whose data was 
Adding patients 
• Add a new patient 
• Find an old patient 
Selecting clinical trials 
• Choose candidate trials 
• View available trials 
Entering initial data 
• Answer initial questions 
• Change previous answers 
Entering medical data 
• Enter test results 
• View eligibility decisions 
Revising medical data 
• View test results 
• Change some results 
Revising test data 
• View test status 
• Change test status 
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entered previously and may resume entering data for them. There is an option to optimize 
cost or data entry when testing. As shown in Figure 8, if the user selects “Cost Version”, 
cost is optimized and if the “No Cost Version” is selected, data entry is optimized.  
 
 
Figure 8: Initial Patient Entry Page 
 
 
Figure 9: Initial Questions Page 
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After the patient’s name and identification are added, the system presents 14 
initial questions as shown in Figure 9. These are general information questions like 
patient’s age, sex, etc. and are generally used in most of the clinical trials. After the user 
has entered the initial information, the next screen is a list of available trials for which the 
patient’s eligibility can be checked. At least one of the clinical trials must be selected. In 
Figure 10 five clinical trials of the available 17 were selected.  
 
 
Figure 10: Clinical Trial Selection Page 
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The system then checks the eligibility of the patient for the selected trials. If it 
needs more information to determine the eligibility then it makes a list of missing 
information questions and reorders the questions optimizing cost or data-entry as selected 
by the user. It then presents the top ten questions of the reordered question list on the next 
page as shown in Figure 11.  
 
 
Figure 11: Data Entry Page. The System Asks for More Information to Determine 
Patient's Eligibility. 
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Figure 12: Status of all Clinical Trials 
 
At any time the user can check the eligibility status of the clinical trials by 
clicking the drop down box as shown in Figure 12. The system keeps on presenting 
questions until the eligibility of all the clinical trials for the given patient is known. The 
user can stop entering data at any point. Data entry for the patient can be reinitiated at any 
later time by using the search option shown in Figure 8.    
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Figure 13: Explanation of a Decision by Explanation Sub-System 
 
At any time you can click on why button and the explanation sub-system will 
justify the system’s decisions as shown in Figure 13. Figure 14 appears when the 
patient’s eligibility for all the clinical trials is decided and there is no more information 
needed.  
 
 
Figure 14: System after Eligibility of all Clinical Trials is Decided 
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Figure 15: Status of all Available Tests for the Patient 
 
At any time you can also check the status of the tests know for the current trials. Figure 
15 shows the test status of all the tests for the given patient. There are three statuses for 
the tests: a) Done before, b) Done, and, c) Not done. “Done before” means that the test 
was already done before the patient was checked for enrollment in a clinical trial. This 
gives the correct cost incurred for determining eligibility for the patient as the system will 
not count the cost of such tests in total cost for the patient. “Done” tests are the ones done 
to obtain more information to decide a patient’s eligibility for clinical trials. Similarly 
“Not done” are the tests that are available in the system but are still not done for the 
patient. At any point the user can change the status of any test.  
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Chapter 5 
Experiments and Results
5.1 Analytical Experiments 
Data of patients treated at the Moffitt Cancer Center was used to compare the system’s 
results with that of clinicians. Results from the application of various heuristics are also 
compared. The first set of experiments were done on retrospective data from 187 patient 
charts. Table 1 shows the comparison of automated assignment by the system and manual 
assignment by clinicians at Moffitt Cancer Center. These experiments were started by 
Kokku [33]. The results are also published in IEEE SMC 2003 conference [14]. 
 
Table 1: Results of Matching Retrospective 187 Patients to Clinical Trials 
Clinical 
Trial 
Same 
Matches 
New 
Matches 
Missing 
Data 
10822 10  5  0 
10840  0 19  3 
11072 48 26 19 
11378  4 19  3 
11992  5  6  0 
12100  8 20 13 
12101 20 30  0 
 
Table 1 shows the number of patients that were eligible for a particular trial. “Same 
Matches” column indicates the patients who were found eligible by the system and were 
also found eligible by the clinicians. The “New Matches” column indicates the patients 
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who were found eligible by the system but were potentially missed by the clinicians. The 
“Missing Data” column indicates the patients that did not have enough information to 
determine their eligibility. All the patients are not tested for all the clinical trials and thus 
some of them do not have some tests performed that are essential to determine eligibility 
for a specific clinical trial. Also the data was retrospective, thus the patients were not 
undergoing treatment at the Moffitt Cancer Center.  
Some questions, which were generally consent-based questions, were answered 
“Yes” while performing the experiments as we had no actual way to determine their 
answers. Below are a few such questions: 
1. Is the patient willing to sign the consent form? 
2. Does the patient have at least sixth grade education? 
3. Is the patient willing to use contraceptives? 
The next set of experiments were done on 169 patients who were getting treatment at 
Moffitt Cancer Center at the time of experiments. The results are shown in Table 2. 
Table 2: Results of Matching Current 169 Patients to Clinical Trials 
Clinical 
Trial 
Number of 
Tested 
Patients 
Same 
Matches 
Missing 
Info 
New 
Matches 
11132     7   4 1   1 
11931 169   2 5 26 
11971 159   4 0   0 
12100 162   0 0   5 
12101 166 11 6 52 
12385   42   0 0 19 
12601 162   0 3   1 
12643   63 18 2 34 
12757   58   1 4   3 
12775 133 23 6 17 
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Table 3: Detailed Classification of New Matches Found 
Clinical 
Trial 
New 
Matches 
New 
Matches 
with no 
enrollment 
New 
Matches 
with no 
conflict 
New 
Matches 
with 
conflict 
% of 
"Assignable" 
New Matches 
over number of 
checked patients 
% of "Actual" 
Enrollment 
over number 
of checked 
patients 
11132   1   0   1   0 14.29% 57.14% 
11931 26 15 11   0 15.38% 1.78% 
11971   0   0   0   0 0.00% 2.52% 
12100   5   4   1   0 3.09% 0.00% 
12101 52 33   6 13 23.49% 6.63% 
12385 19   9   2   8 26.19% 0.00% 
12601   1   1   0   0 0.62% 0.00% 
12643 34 24 10   0 53.97% 30.16% 
12757   3   2   1   0 5.17% 1.72% 
12775 17 11   3   3 10.53% 18.80% 
 
Table 2 is similar to Table 1 which was explained previously. Table 3 categorizes the 
new matches found by the system. The third column of Table 3 specifies the number of 
new matches in which the patient was not enrolled in any clinical trial. Thus this number 
represents the patients who were found eligible for some clinical trial by the system, but 
were never enrolled in any clinical trial by the clinicians. The fourth column indicates the 
number of matches in which the patient was assigned to a clinical trial but there was still 
a clinical trial to which she could be assigned. Many clinical trials are compatible and 
thus a patient can be in two clinical trials at once. Such clinical trials are called 
compatible clinical trials. Thus the numbers in fourth column indicates the patients who 
were assigned to a clinical trial but there was an available compatible clinical trial to 
which they were not assigned. The fifth column indicates the number of matches found in 
which the patient was already enrolled in an incompatible trial. Thus this match has no 
significance as the patient could not have been assigned to the matching trial anyway. 
The sixth column indicates the percentage of assignable matches found over the number 
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of patients checked. The number of assignable matches found, is the summation of the 
third and fourth columns. This indicates the matches in which the patient could have been 
safely enrolled in a new clinical trial to which the patient was not previously assigned. 
The last column is the percentage of actual enrollment in that clinical trial. Note that in 
the majority of protocols, the percentage of new assignable matches found is greater than 
the actual enrollment.  
The results clearly show that the system was able to detect many matches which 
were potentially missed by clinicians. Given that fact that many clinical trials fail due to 
under-recruiting [11, 22, 33], the system can potentially play a crucial role in the success 
of a clinical trial.  
5.2 Cost Saving Experiments 
In case of lack of information to determine a patient’s eligibility for a clinical trial, the 
clinicians order specific tests to be performed on the patient to obtain relevant 
information. Research suggests that test costs can be saved if we optimize the test 
ordering [1, 11, 14]. The system’s reordering agent reorders the questions presented by 
the system to the user. This, in turn, results in reordering of the tests as tests needs to be 
performed to obtain answers to the questions.  Reordering heuristics were designed to 
optimize the cost as explained in the system design section. Tables 4 and  5 show the cost 
saving information for the retrospective 183 patients and current 169 patients 
respectively.  
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Table 4: Average Dollar Cost Savings for 187 Retrospective Patients 
Average Dollar Cost 
Clinical 
Trial 
Without Test 
Reordering 
With Test 
Reordering 
10822 $70 $11 
10840 $0 $0 
11072 $209 $60 
11378 $35 $19 
11992 $0  $0 
12100  $0  $0 
12101   $0  $0 
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Figure 16: Graph Showing Average Dollar Cost Savings for Retrospective Patients 
 
Table 5: Average Dollar Cost Savings for 169 Current Patients 
Average Dollar Cost 
Clinical 
Trial 
Without Test 
Reordering 
With Test 
Reordering 
11132 $0 $0 
11931 $0 $0 
11971 $192 $192 
12100 $0 $0 
12101 $0 $0 
12385 $0 $0 
12601 $36 $3 
12643 $0 $0 
12757 $107 $107 
12775 $0 $0 
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Figure 17: Graph Showing Average Dollar Cost Savings for Current Patients 
 
5.3 Probabilistic Experiments 
It was noted that medical test results were highly probabilistic in nature. Most test results 
can be estimated with reasonable accuracy before the test is performed. Given enough 
data this knowledge can be used to reorder tests and to optimize data entry needed to 
determine the eligibility of a patient. Also it was noted that over time, clinicians typically 
get a good estimate of what information is likely to be most crucial in determining the 
eligibility of a patient and prefer to get that information first. We developed a 
probabilistic knowledge base on the same principles. Whenever a question is answered 
by a user, the system records it. If answering the question made a patient ineligible for a 
clinical trial, this is recorded too. Thus we get a basic ratio of the number of times a 
question was asked, to the number of times it made a patient ineligible for a particular 
protocol. Treating this as a probability we reorder the questions, with the questions 
having a higher probability of ruling a patient out of a clinical trial being asked first. The 
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idea is that if a patient is ineligible then the question which is most likely to determine 
she is ineligible, from past experience, is asked first and this will reduce data entry. This 
method also closely mimics the method adopted by clinicians and thus can increase 
acceptability of the system by medical personnel.  
The system begins by assigning a 50% probability to all the questions. The 
probability is modified as the system sees new evidence. To test the effectiveness of this 
technique we did a ten-fold cross validation. We randomly selected 90% of the patients 
and their data was used to generate a probabilistic knowledge base for the system. The 
remaining 10% of the patients were tested using the system which used this probabilistic 
knowledge base to reorder the questions. This process was repeated ten times with each   
10% of the testing patients being unique. Six clinical trials were used in the experiments. 
These six clinical trials were selected out of about 15 possible clinical trials, as these 
trials were in “open” status for a long enough duration during the experiments to have an 
adequate number of patients being tested for those clinical trials. In the probabilistic 
experiments it was necessary to train the system on an adequate number of patients 
before it can be used to reorder questions for other patients. We selected 90 patients at 
random from our list of patients and used their data in experiments. As mentioned above, 
a ten-fold cross validation was carried out, so that the system was trained on 81 patients 
and the remaining 9 patients were tested using the system. 
 Table 6 shows the results of each fold of the cross validation. Table 7 shows 
results of the cross validation per clinical trial. 
 
 
 37 
Table 6: Individual Test Results for Ten-Fold Cross Validation 
Ten-fold cross validation 
Average number of questions 
Test 
Number 
Probabilistic 
System 
Analytical 
System Difference 
Difference 
% 
1 16.67 20.75 4.08 19.68 
2 15.17 17.00 1.83 10.78 
3 15.83 17.58 1.75 9.95 
4 15.75 18.25 2.50 13.70 
5 13.83 16.67 2.83 17.00 
6 15.58 17.75 2.17 12.21 
7 15.83 18.25 2.42 13.24 
8 15.50 16.83 1.33 7.92 
9 16.50 18.50 2.00 10.81 
10 15.83 19.17 3.33 17.39 
Total 15.65 18.08 2.43 13.42 
 
Table 7: Results of Ten-Fold Cross Validation per Protocol 
Ten-fold cross validation 
Average number of questions 
Protocol 
Probabilistic 
System 
Analytical 
System Difference 
Difference 
% 
11931 15.35 18.90 3.55 18.78 
12100 13.85 13.95 0.10 0.72 
12101 21.65 24.75 3.10 12.53 
12521 14.75 19.05 4.30 22.57 
12601 13.90 15.70 1.80 11.46 
12777 14.40 16.10 1.70 10.56 
Average 15.65 18.08 2.43 13.42 
 
As seen in Table 7 the probabilistic system reduces data entry by 13.42% on average as 
compared to the analytical system. The average number of questions asked by the system 
is reduced by 2.43. One important observation is that the probabilistic system always 
asks fewer questions than the analytical system for all the patients tested. Using the t-test, 
the probabilistic system is statistically significantly better at the 99.99% confidence 
interval.   
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Table 8: Standard Deviation for Ten-Fold Cross Validation 
Standard deviation 
Protocol 
New 
System 
No Cost 
Version 
11931 7.44 6.11 
12100 1.39 1.61 
12101 7.44 6.11 
12521 5.39 6.54 
12601 3.67 5.55 
12777 5.69 7.26 
 
Also note that as shown in the system’s interface design diagrams, the system asks 14 
basic questions after one enters a patient into the system. These questions are general 
questions which are used in almost all trials, like patient’s age, sex, etc. If the patient’s 
eligibility is still not determined for all the trials for which her eligibility is tested, the 
system asks for further information. Thus technically you answer a minimum of 14 
questions for a patient as it is very unusual to not to have information about any of those 
questions. For such patients who get ruled out of a clinical trial after the questions on the 
initial page, the number of questions asked in both the systems remains the same as there 
is no reordering of questions. Table 9 shows the average number of questions when we 
exclude such patients from our experiment. The probabilistic system asks 3.69 fewer 
questions on an average than analytical system which is 18.53% less then analytical 
system. It saves up to 33% of the data entry for 12601, which is the maximum.  
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Table 9: Results Excluding Patients who were Ineligible by Initial Questions 
Ten-fold cross validation 
Average number of questions 
Protocol 
Probabilistic 
System 
Analytical 
System Difference 
Difference 
% 
11931 16.71 21.79 5.07 23.28 
12100 14.75 15.25 0.50 3.28 
12101 22.05 25.32 3.26 12.89 
12521 14.75 19.05 4.30 22.57 
12601 14.60 21.80 7.20 33.03 
12777 14.42 16.21 1.79 11.04 
Average 16.21 19.90 3.69 18.53 
 
5.4 Eligibility Probability 
A major disadvantage of using an analytical approach to finding eligibility is that even in 
the absence of a single piece of evidence, we cannot predict anything about the eligibility 
of a patient. On the other hand, with a probabilistic approach, we can make some 
predictions about the eligibility. Papaconstantinou [10] showed in his experiment that by 
using Bayesian Networks, we can determine a patient’s eligibility in the absence of some 
evidence. In our rule based system, we tried to use the independent probabilities that we 
had for each question, to generate a prediction about a patient’s eligibility probability in 
the absence of evidence. As explained before in the system design section, we assume 
that all questions are independent, so the eligibility probability for a protocol is the 
product of the individual probabilities that a question does not rule out a patient, of all the 
questions of that protocol. As we enter more information in the system, if the patient is 
ruled ineligible by the system, her eligibility is 0, and if she is eligible then her eligibility 
probability is 1. If we still need more information, we recalculate the eligibility 
probability as the product of eligibility probability of all the unanswered questions.  
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One of the uses of the eligibility probability can be to try to quickly assign a 
patient to a clinical trial. This can be achieved by generating an initial eligibility 
probability for all the available trials for that patient. We then check the eligibility of the 
patient for the trial which has the highest eligibility probability. After every piece of 
information, the probabilities are regenerated and the system asks for more information 
about the trial with the highest eligibility probability until the patient is found eligible for 
a trial or is determined ineligible for all the trials. The system stops seeking further 
information after the patient is found eligible for a clinical trial as the purpose of these 
experiments is to find a single matching protocol with least the number of questions 
being answered. To test the effectiveness of this approach we did a ten-fold cross 
validation on the available patients using this approach. We used six clinical trials. We 
compare the results with the analytical system in which we stop answering questions 
when it finds a clinical trial for which the patient is eligible. Results are shown in Table 
10. 
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Table 10: Ten-Fold Cross-Validation for Heuristic that Uses Eligibility Probability 
Ten-fold cross validation 
Average number of questions 
Test 
Number 
Probabilistic 
System 
Analytical 
System Difference 
Difference 
% 
1 22.33 28.67 6.33 22.09 
2 30.67 34.33 3.67 10.68 
3 31.33 24.33 -7.00 -28.77 
4 30.00 33.00 3.00 9.09 
5 19.67 25.00 5.33 21.33 
6 20.67 31.67 11.00 34.74 
7 28.33 33.00 4.67 14.14 
8 24.00 36.67 12.67 34.55 
9 21.67 22.67 1.00 4.41 
10 17.67 24.33 6.67 27.40 
Average 24.63 29.37 4.73 16.12 
 
As shown in Table 10, using the eligibility probability in reordering heuristic saves 
16.12% of data entry. For the third test in ten-fold cross validation, the probabilistic 
system asks more questions then the analytical system. This is because the protocols for 
which the patient is more likely to be eligible are tested first in the probabilistic system 
and the patients were ineligible for that protocol. Thus the number of questions asked 
increases as compared to the analytical system. Using the t-test, the probabilistic system 
is statistically significantly better at the 95% confidence interval. 
Although the method gave good results, it had an inherent drawback that the 
probabilities were not normalized and thus the resultant probabilities were a very low 
number that were inappropriate for providing feedback to users. As discussed in the 
“System Design” section, we used Bayes probabilities to compute probabilities that were 
more suitable to give appropriate feedback. The same set of 90 patients that were used in 
the previous experiments were used to conduct 10-fold cross validation experiments.   
Figure 11 shows the results.  
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Table 11: Ten-Fold Cross-Validation for Reordering Agent that Uses the Bayes Method 
to Compute Eligibility Probability 
Ten-fold cross validation 
Average number of questions 
Test 
Number 
Probabilistic 
System 
Analytical 
System Difference 
Difference 
% 
1 20.67 28.67 8.00 27.91 
2 29.00 34.33 5.33 15.53 
3 31.67 24.33 -7.33 -30.14 
4 26.33 33.00 6.67 20.20 
5 22.33 25.00 2.67 10.67 
6 18.67 31.67 13.00 41.05 
7 25.67 33.00 7.33 22.22 
8 22.67 36.67 14.00 38.18 
9 19.33 22.67 3.33 14.71 
10 17.33 24.33 7.00 28.77 
Average 23.37 29.37 6.00 20.43 
 
The results show that Bayes method of computing eligibility probability and using 
it in reordering the questions reduces the data entry needed by 20.43 % on an average. 
Also the probabilities generated were more appropriate for feedback as the probabilities 
computed were real probabilities unlike the previous method where they were not 
normalized and thus were very small numbers.  Using the t-test, the probabilistic system 
is statistically significantly better at the 95% confidence interval. 
As shown by the results, the reordering agent using Bayes method for computing 
eligibility probability reduces data entry more then the reordering agent using the 
previous method. Although the Bayes method is know to provide with more accurate 
probability, the previous method was tried as it had an important feature that the 
eligibility probability was dependent on the number of questions in the clinical trial. As 
the individual probabilities of each question was very small number, the more questions 
in the eligibility probability, the lesser the eligibility probability gets as it was the product 
of individual probability of each question. This method is biased towards the clinical 
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trials with lesser number of questions, which can help optimize data entry. Out of the six 
clinical trial used in the experiments, clinical trial number 12777 has four questions and 
clinical trial 12521 have 34 questions. Is such a scenario it might be optimal to check the 
eligibility of clinical trial 12777 before 12521 even if 12521 has higher rate or 
enrollment. If 12521 have better rate or enrollment then 12777 then the reordering agent 
using Bayes method for calculating eligibility probability will estimate a higher eligibility 
probability for 12521 and ask for more information about that clinical trial. Whereas, the 
reordering agent that estimates eligibility probability by product of individual questions 
will most certainly estimate a higher eligibility probability for 12777. The experiment 
results suggest that when the reordering agent uses Bayes method to estimate eligibility 
probability, it results in a more data entry efficient agent.  
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Chapter 6 
Conclusions and Future Work
6.1 Conclusions 
Recruiting patients to clinical trials is very time and labor intensive work. Many clinical 
trials fail due to under recruitment. The system presented here has found a substantial 
number of matches potentially missed by clinicians. Thus the system can play a critical 
part in the success of a clinical trial. Also the web-based interface of the system makes it 
possible to have a central system which can be accessed by clinical personnel from any 
medical institute around the country. All large research centers have clinical trials of their 
own and it is very hard to exchange the trial information between them as the same trials 
can be interpreted in a different way by different clinicians. Having an electronic version 
of the clinical trials encoded using our knowledge entry system can make sharing of 
clinical trials between different hospitals very convenient and effective. This in turn can 
increase accrual for clinical trials as the pool of potential participants increases.  
The system also effectively reorders the tests and reduces the cost incurred in 
determining eligibility.  We developed the probabilistic agent which accumulates 
probabilistic knowledge over time.  Data entry was successfully optimized by as much as 
30% using the probabilistic reordering agent. The testing system makes it possible to 
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efficiently check the performance of different reordering heuristics. The system also 
mimics human behavior which may increase its acceptability to medical personnel. 
6.2 Future Work 
The system was designed to match patients to clinical trials of any kind, but currently 
only breast cancer clinical trials are being implemented. The system currently reorders to 
optimize cost and data entry but it also has provisions to incorporate pain measures for 
each test and reorder to minimize pain for the patients. These options still need to be 
explored.  
The probabilistic reordering agent use independent probabilities of each question 
and estimate eligibility probability using Bayes rule . Other probabilistic methods need to 
be explored to try to improve the reordering and save more data entry and costs. In the 
experiments conducted, the probabilistic agents were trained on 81 patients. The 
effectiveness of the agents needs to be investigated when different number of patients are 
used in training.  
The system currently is a web-based CGI application. Thus every time the system 
is accessed, it has to regenerate all the graphs and load parts of knowledge into memory. 
Currently we are implementing a port-listening version of the system, which keeps all the 
graphs and needed knowledge in memory until needed. This will eventually improve the 
responsiveness of the system even when the patient is being tested for a large number of 
clinical trials at once. 
The reordering heuristics either use the probabilistic or the analytical approach. 
Heuristics that use both approaches together still need to be implemented and tested. 
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